======= SOCS3 =======
== Gene Information ==
* **Official Symbol**: SOCS3
* **Official Name**: suppressor of cytokine signaling 3
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9021|9021]]
* **UniProt**: [[https://www.uniprot.org/uniprot/O14543|O14543]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=SOCS3&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20SOCS3|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/604176|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: This gene encodes a member of the STAT-induced STAT inhibitor (SSI), also known as suppressor of cytokine signaling (SOCS), family. SSI family members are cytokine-inducible negative regulators of cytokine signaling. The expression of this gene is induced by various cytokines, including IL6, IL10, and interferon (IFN)-gamma. The protein encoded by this gene can bind to JAK2 kinase, and inhibit the activity of JAK2 kinase. Studies of the mouse counterpart of this gene suggested the roles of this gene in the negative regulation of fetal liver hematopoiesis, and placental development. [provided by RefSeq, Jul 2008].
* **UniProt Summary**: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC- CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST (By similarity). {ECO:0000250, ECO:0000269|PubMed:15601820}.
|SH2|
|SOCS box|
|spongiotrophoblast differentiation|
|spongiotrophoblast layer development|
|negative regulation of tyrosine phosphorylation of STAT protein|
|branching involved in labyrinthine layer morphogenesis|
|trophoblast giant cell differentiation|
|1-phosphatidylinositol-3-kinase regulator activity|
|interleukin-6-mediated signaling pathway|
|phosphatidylinositol 3-kinase complex|
|negative regulation of receptor signaling pathway via JAK-STAT|
|negative regulation of receptor signaling pathway via STAT|
|labyrinthine layer morphogenesis|
|regulation of response to interferon-gamma|
|regulation of interferon-gamma-mediated signaling pathway|
|cell differentiation involved in embryonic placenta development|
|embryonic placenta morphogenesis|
|protein kinase inhibitor activity|
|placenta blood vessel development|
|cellular response to interleukin-6|
|negative regulation of insulin receptor signaling pathway|
|response to interleukin-6|
|negative regulation of cellular response to insulin stimulus|
|receptor signaling pathway via JAK-STAT|
|receptor signaling pathway via STAT|
|phosphotyrosine residue binding|
|labyrinthine layer development|
|phosphatidylinositol phosphorylation|
|negative regulation of peptidyl-tyrosine phosphorylation|
|regulation of phosphatidylinositol 3-kinase activity|
|regulation of lipid kinase activity|
|regulation of insulin receptor signaling pathway|
|lipid phosphorylation|
|positive regulation of tyrosine phosphorylation of STAT protein|
|regulation of cellular response to insulin stimulus|
|regulation of tyrosine phosphorylation of STAT protein|
|positive regulation of receptor signaling pathway via JAK-STAT|
|regulation of phospholipid metabolic process|
|embryonic placenta development|
|positive regulation of receptor signaling pathway via STAT|
|cellular response to leukemia inhibitory factor|
|response to leukemia inhibitory factor|
|regulation of receptor signaling pathway via JAK-STAT|
|regulation of receptor signaling pathway via STAT|
|negative regulation of inflammatory response|
|placenta development|
|morphogenesis of a branching epithelium|
|regulation of cytokine-mediated signaling pathway|
|phosphatidylinositol metabolic process|
|morphogenesis of a branching structure|
|regulation of response to cytokine stimulus|
|positive regulation of peptidyl-tyrosine phosphorylation|
|lipid modification|
|negative regulation of defense response|
|negative regulation of protein kinase activity|
|negative regulation of kinase activity|
|regulation of peptidyl-tyrosine phosphorylation|
|negative regulation of transferase activity|
|glycerophospholipid metabolic process|
|regulation of inflammatory response|
|post-translational protein modification|
|negative regulation of response to external stimulus|
|phospholipid metabolic process|
|in utero embryonic development|
|glycerolipid metabolic process|
|regulation of lipid metabolic process|
|negative regulation of protein phosphorylation|
|reproductive structure development|
|reproductive system development|
|morphogenesis of an epithelium|
|embryonic organ development|
|negative regulation of phosphorylation|
|regulation of innate immune response|
|blood vessel development|
|vasculature development|
|cardiovascular system development|
|regulation of response to biotic stimulus|
|negative regulation of phosphate metabolic process|
|negative regulation of phosphorus metabolic process|
|tissue morphogenesis|
|embryonic morphogenesis|
|negative regulation of protein modification process|
|chordate embryonic development|
|embryo development ending in birth or egg hatching|
|developmental process involved in reproduction|
|regulation of growth|
|cytokine-mediated signaling pathway|
|protein ubiquitination|
|regulation of defense response|
|protein modification by small protein conjugation|
|regulation of multi-organism process|
|negative regulation of catalytic activity|
|regulation of protein kinase activity|
|circulatory system development|
|regulation of kinase activity|
|organophosphate metabolic process|
|negative regulation of apoptotic process|
|negative regulation of programmed cell death|
|cellular lipid metabolic process|
|positive regulation of cell differentiation|
|regulation of transferase activity|
|embryo development|
|protein modification by small protein conjugation or removal|
|negative regulation of cell death|
|cellular response to cytokine stimulus|
|positive regulation of protein phosphorylation|
|negative regulation of cellular protein metabolic process|
|positive regulation of phosphorylation|
|regulation of response to external stimulus|
|response to cytokine|
|negative regulation of protein metabolic process|
|epithelium development|
|positive regulation of phosphate metabolic process|
|positive regulation of phosphorus metabolic process|
|negative regulation of molecular function|
|regulation of immune response|
|lipid metabolic process|
|positive regulation of protein modification process|
|negative regulation of signal transduction|
|phosphorylation|
|negative regulation of cell communication|
|negative regulation of signaling|
|positive regulation of developmental process|
|reproductive process|
|reproduction|
|regulation of protein phosphorylation|
|regulation of response to stress|
|regulation of apoptotic process|
|regulation of programmed cell death|
|regulation of phosphorylation|
|positive regulation of cellular protein metabolic process|
|negative regulation of response to stimulus|
|positive regulation of signal transduction|
|regulation of immune system process|
|regulation of cell death|
|intracellular signal transduction|
|positive regulation of protein metabolic process|
|tissue development|
|regulation of phosphate metabolic process|
|regulation of phosphorus metabolic process|
|regulation of cell differentiation|
|positive regulation of cell communication|
|positive regulation of signaling|
|regulation of protein modification process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp179|Combretastatin A4 0.002 to 0.003μM day4 R04 exp179]]|-1.76|
|[[:results:exp341|BRD2 inhibitor II 20μM R07 exp341]]|2.4|
^Gene^Correlation^
|[[:human genes:h:hgc6.3|HGC6.3]]|0.424|
Global Fraction of Cell Lines Where Essential: 32/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|3/26|
|breast|1/33|
|central nervous system|5/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|1/16|
|kidney|3/21|
|liver|1/20|
|lung|1/75|
|lymphocyte|0/16|
|ovary|3/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|3/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|4/22|
|urinary tract|0/29|
|uterus|1/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3266
* **Expression level (log2 read counts)**: -3.8
{{:chemogenomics:nalm6 dist.png?nolink |}}